Analysis of BRCA1 and RAD51C Promoter Methylation in Italian Families at High-Risk of Breast and Ovarian Cancer

Previous studies on breast and ovarian carcinoma (BC and OC) revealed constitutional BRCA1 and RAD51C promoter hypermethylation as epigenetic alterations leading to tumor predisposition. Nevertheless, the impact of epimutations at these genes is still debated. One hundred and eight women affected by BC, OC, or both and considered at very high risk of carrying BRCA1 germline mutations were studied. All samples were negative for pathogenic variants or variants of uncertain significance at BRCA testing. Quantitative BRCA1 and RAD51C promoter methylation analyses were performed by Epityper mass spectrometry on peripheral blood samples and results were compared with those in controls. All the 108 analyzed cases showed methylation levels at the BRCA1/RAD51C promoter comparable with controls. Mean methylation levels (± stdev) at the BRCA1 promoter were 4.3% (± 1.4%) and 4.4% (± 1.4%) in controls and patients, respectively (p > 0.05; t-test); mean methylation levels (± stdev) at the RAD51C promoter were 4.3% (± 0.9%) and 3.7% (± 0.9%) in controls and patients, respectively (p > 0.05; t-test). Based on these observations; the analysis of constitutional methylation at promoters of these genes does not seem to substantially improve the definition of cancer risks in patients. These data support the idea that epimutations represent a very rare event in high-risk BC/OC populations.

[1]  L. Saal,et al.  Whole-genome-sequencing of triple negative breast cancers in a population-based clinical study , 2019, Nature Medicine.

[2]  Kylie L. Gorringe,et al.  Combined tumor sequencing and case/control analyses of RAD51C in breast cancer. , 2019, Journal of the National Cancer Institute.

[3]  P. Lønning,et al.  Constitutional Mosaic Epimutations - a hidden cause of cancer? , 2019, Cell stress.

[4]  S. Manoukian,et al.  Constitutive BRCA1 Promoter Hypermethylation Can Be a Predisposing Event in Isolated Early-Onset Breast Cancer , 2019, Cancers.

[5]  Javier Santoyo-Lopez,et al.  A Dominantly Inherited 5′ UTR Variant Causing Methylation-Associated Silencing of BRCA1 as a Cause of Breast and Ovarian Cancer , 2018, American journal of human genetics.

[6]  N. Al-Moghrabi,et al.  Methylation of BRCA1 and MGMT genes in white blood cells are transmitted from mothers to daughters , 2018, Clinical Epigenetics.

[7]  A. Howell,et al.  White Blood Cell BRCA1 Promoter Methylation Status and Ovarian Cancer Risk , 2018, Annals of Internal Medicine.

[8]  L. Martorell,et al.  Germline promoter hypermethylation in BRCA1 and BRCA2 genes is not present in hereditary breast cancer patients , 2018, Clinical and Translational Oncology.

[9]  Rochelle L. Garcia,et al.  Clinical characteristics and outcomes of patients with BRCA1 or RAD51C methylated versus mutated ovarian carcinoma. , 2017, Gynecologic oncology.

[10]  O. Mariani,et al.  Genomic hallmarks of homologous recombination deficiency in invasive breast carcinomas , 2016, International journal of cancer.

[11]  Lara E Sucheston-Campbell,et al.  Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Á. Carracedo,et al.  Prevalence of MLH1 constitutional epimutations as a cause of Lynch syndrome in unselected versus selected consecutive series of patients with colorectal cancer , 2015, Journal of Medical Genetics.

[13]  F. Berrino,et al.  Estimate of the penetrance of BRCA mutation and the COS software for the assessment of BRCA mutation probability , 2015, Familial Cancer.

[14]  P. Peltomäki.  Epigenetic mechanisms in the pathogenesis of Lynch syndrome , 2014, Clinical genetics.

[15]  Jian-Bing Fan,et al.  Clinical Characteristics of Ovarian Cancer Classified by BRCA1, BRCA2, and RAD51C Status , 2014, Scientific Reports.

[16]  S. Narod,et al.  Promoter methylation of BRCA1 in triple-negative breast cancer predicts sensitivity to adjuvant chemotherapy. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  T. Haaf,et al.  Constitutive promoter methylation of BRCA1 and RAD51C in patients with familial ovarian cancer and early-onset sporadic breast cancer , 2012, Human molecular genetics.

[18]  T. Taguchi,et al.  BRCA1 promoter methylation in peripheral blood cells is associated with increased risk of breast cancer with BRCA1 promoter methylation , 2011, Breast Cancer Research and Treatment.

[19]  Graham G. Giles,et al.  Constitutional Methylation of the BRCA1 Promoter Is Specifically Associated with BRCA1 Mutation-Associated Pathology in Early-Onset Breast Cancer , 2010, Cancer Prevention Research.

[20]  J. Herman,et al.  BRCA1 CpG island hypermethylation predicts sensitivity to poly(adenosine diphosphate)-ribose polymerase inhibitors. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Dieter Niederacher,et al.  Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene , 2010, Nature Genetics.

[22]  E. Friedman,et al.  Promoter methylation patterns of ATM, ATR, BRCA1, BRCA2 and P53 as putative cancer risk modifiers in Jewish BRCA1/BRCA2 mutation carriers , 2009, Breast Cancer Research and Treatment.

[23]  A. Richardson,et al.  BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles , 2005, Breast Cancer Research and Treatment.